Modality
ERT
MOA
WEE1i
Target
CFTR
Pathway
Angiogenesis
NMOSDCeliac
Development Pipeline
Preclinical
Dec 2025
→ Dec 2026
PreclinicalCurrent
NCT07516016
2,911 pts·NMOSD
2025-12→2026-12·Active
2,911 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-12-199mo awayInterim· NMOSD
Trial Timeline
2026Q2Q3Q4
Preclinical
Active
Catalysts
Interim
2026-12-19 · 9mo away
NMOSD
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07516016 | Preclinical | NMOSD | Active | 2911 | DAS28 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-8637 | Johnson & Johnson | NDA/BLA | CD20 | |
| Nidasacituzumab | Eli Lilly | Approved | CFTR | |
| MRK-853 | Merck & Co | Phase 1 | PRMT5 | |
| Datoglumide | AbbVie | Approved | CFTR | |
| SNY-7254 | Sanofi | Phase 2 | CFTR | |
| SNY-5894 | Sanofi | Approved | CFTR | |
| Doxafotisoran | Daiichi Sankyo | Phase 1 | Cl18.2 | |
| GMA-1468 | Genmab | NDA/BLA | PI3Kα | |
| Sovarelsin | BioMarin | Phase 2 | CFTR | |
| Fixatuximab | Legend Biotech | Preclinical | CFTR |